Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) shares were up 0.1% during mid-day trading on Monday. The company traded as high as $24.4950 and last traded at $23.93. 193,619 shares traded hands during mid-day trading, an increase of 286% from the average daily volume of 50,104 shares. The stock had previously closed at $23.90.
Neoleukin Therapeutics Price Performance
The business has a 50-day moving average of $28.15 and a 200-day moving average of $28.06. The company has a market capitalization of $224.89 million, a P/E ratio of -7.69 and a beta of 1.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics was a Seattle-based biotechnology company focused on designing protein-based medicines using computational methods. Its research centered on therapies intended to harness the immune system to treat cancer and other diseases. The company’s lead program, NL-201, was an engineered protein designed to mimic the activity of the immune-signaling molecules interleukin-2 and interleukin-15. Neoleukin advanced the candidate into early-stage clinical testing to evaluate its safety and potential as a cancer treatment.
Recommended Stories
- Five stocks we like better than Neoleukin Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
